KRAS and neoplasm: Its ability to bind to high-affinity EGFR ligands (e.g., HB-EGF, TGFα, BTC, and EGF) contributes to its anti-tumor efficacy against KRAS-mutant colorectal cancer (CRC) in a patient-derived xenograft (PDX) model resistant to cetuximab treatment [14].